CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Michael Severino

Chief Executive Officer, Sarepta Therapeutics, Inc.

Search every verified Michael Severino interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Michael Severino, CEO of Tessera Therapeutics, discussed the company’s progress in genetic medicine during appearances at the JP Morgan Healthcare Conference in January 2026. He announced regulatory clearance to begin clinical trials for a treatment for alpha-1 antitrypsin deficiency (AATD), a condition he described as affecting 200,000 to 250,000 patients in the US and Europe. Severino stated that the company’s gene-writing platform aims to correct over 90% of alleles to the wild-type sequence in preclinical systems, which he said could lead to near-complete conversion of normal protein production. He also discussed a sickle cell disease program, noting that the company had reprogrammed its lipid nanoparticle delivery technology to target long-term hematopoietic stem cells, and mentioned a global 50-50 collaboration with Regeneron for development and commercialization of the AATD program. In earlier appearances, Severino described gene writing as a technology that can make changes to the human genome, from correcting single-letter errors to writing entire genes, and emphasized the use of non-viral lipid nanoparticle delivery to avoid immunogenicity and enable redosing. He contrasted this approach with viral vectors, which he said can be toxic and inefficient. Severino also highlighted partnerships, including one with the Gates Foundation aimed at ensuring therapies reach patients in underserved regions, and expressed optimism about the field’s potential to deliver cures for genetic diseases, stating that the technology could transform the practice of medicine over the next three to five years.

Recent appearances

  • EP 223: Live at JPM: Rewriting disease with genetic medicine with Michelle Werner & Mike Severino

    January 22, 2026 · 📺 Sano Genetics

    This week on The Genetics Podcast, Patrick is joined for a special recording at the Flagship Pioneering studio during JPM 2026 by Michelle Werner, CEO of Alltrna, and Michael Severino, CEO of Tessera Therapeutics. They discuss the molecular mechanisms behind Alltrna’s engineered tRNA and Tessera’s gene-writing platforms, why 2026 marks a major inflection point as both programs enter the clinic, and considerations around trial design, patient needs, and delivering therapies at scale. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Michelle & Michael 01:29 Overview of Alltrna…

    Watch on YouTube ↗

  • 2026 CEO Chat: Michael Severino, Tessera Therapeutics

    January 14, 2026 · 📺 Flagship Pioneering

    Tessera Therapeutics CEO Michael Severino discusses advancing in vivo genetic medicines to create new possibilities for treating disease at its genetic source. About Flagship Pioneering: Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines,…

    Watch on YouTube ↗

  • EP103: Gene Writing with Tessera Therapeutics CEO, Dr. Mike Severino

    March 21, 2024 · 📺 Sano Genetics

    In this episode, Patrick is joined by Dr. Mike Severino, CEO of Tessera Therapeutics and CEO-Partner of Flagship Pioneering. Join us as Mike walks us through Tessera’s approach to treating genetic diseases by rewriting bases, exons, or even whole genes with a novel approach called Gene Writing. 0:00 Intro 1:00 What prompted you to join Flagship Pioneering? 3:32 How is Flagship able to innovate and invent novel therapies in ways that Big Pharma companies may find difficult? 5:00 Introduction to gene writing and the role of Tessera Therapeutics 8:22 The current limitations and challenges of gen…

    Watch on YouTube ↗

  • 2023 Flagship CEO Chat: Mike Severino, CEO of Tessera Therapeutics

    January 11, 2023 · 📺 Flagship Pioneering

    Mike Severino, CEO of Tessera Therapeutics & Flagship Pioneering CEO-Partner, sits down with Lindy Devereux, Senior Director of Communications and Brand, Flagship Pioneering @ JPM 2023. For more on Tessera Therapeutics, visit https://www.tesseratherapeutics.com/. Website: www.flagshipioneering.com Twitter: @FlagshipPioneer Linkedin:   / flagship-pioneering  

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →